Complete coverage on

Pfizer Inc.

Latest Stories

CNNMoney: War against cholesterol gets cheaperupdated: Wed Nov 30 2011 14:45:00

The blockbuster drug Lipitor went generic Wednesday, likely costing its maker billions of dollars in sales, but saving its users a nice sum in their fight against cholesterol.

CNNMoney: Dow slides for seventh week out of eightupdated: Fri Jun 24 2011 18:29:00

Stocks slid deep into the red Friday, as disappointing news from Oracle and Micron Technology weighed heavily on tech stocks, offsetting slightly positive economic reports on U.S. gross domestic product and durable goods orders.

U.S. sales of widely used drug for chickens to be suspendedupdated: Wed Jun 08 2011 18:25:00

Sales of a drug widely used by poultry producers on their flocks will be suspended because a study found the livers of chickens given the drug contain inorganic arsenic -- a cancer-causing agent.

CNNMoney: I want a new drug! Health care stocks on fireupdated: Tue May 03 2011 13:20:00

Remember how last year's controversial health care reform law was supposed to be the death knell for drug stocks and other medical companies? That hasn't exactly happened.

Cable: Pfizer funded dirt-diggingupdated: Fri Dec 10 2010 20:34:00

CNN's Christian Purefoy explains the controversy over leaked cables involving drug trials by Pfizer in Nigeria.

WikiLeaks cable: Pfizer hired investigators to dig dirt on Nigerian AGupdated: Fri Dec 10 2010 20:34:00

In April 2009, U.S. pharmaceutical giant Pfizer reached a financial agreement with a state government in Nigeria on lawsuits brought over an antibiotic that had been given to children during an outbreak of meningitis.

CNNMoney: Precious metals outshine stocksupdated: Mon Dec 06 2010 16:30:00

Precious metals like gold and silver took center stage Monday as few investors showed a willingness to jump into the stock market fray on a day with no major economic news on tap.

CNNMoney: Pfizer CEO leaves 'extremely demanding' jobupdated: Mon Dec 06 2010 08:13:00

Pfizer said CEO Jeffrey Kindler has retired from the job because it had been "extremely demanding" on him personally.

CNNMoney: Stocks headed higher at the openupdated: Tue Nov 02 2010 08:29:00

U.S. stocks were set to open higher Tuesday as the nation headed to the polls for the midterm election and the Federal Reserve geared up for a key two-day meeting.

38,000 more bottles of Lipitor recalled over odor complaintsupdated: Sat Oct 30 2010 08:06:00

Pfizer is recalling an additional 38,000 bottles of the cholesterol-fighting drug Lipitor after reports of an odor linked to the packaging bottles, the drug company said in a statement.

High court allows trial on drug safety to proceedupdated: Mon Jun 21 2010 14:14:00

A lawsuit brought by a breast cancer patient against a major drug company will go forward after the Supreme Court refused to intervene in the dispute.

CNNMoney: Pfizer to cut more jobs and close factoriesupdated: Tue May 18 2010 13:58:00

Pharmaceutical giant Pfizer said Tuesday that it will reduce its staff by another 6,000 jobs and shut down eight factories in its ongoing mission to cut costs in the wake of its merger with Wyeth.

Feds found Pfizer too big to nailupdated: Fri Apr 02 2010 16:44:00

Imagine being charged with a crime, but an imaginary friend takes the rap for you.

CNNMoney: Health care stocks gain after House passes reform billupdated: Mon Mar 22 2010 16:39:00

Health care stocks ended sharply higher Monday as the long-debated health care reform legislation headed to President Obama's desk.

CNNMoney: Health perks for the unemployedupdated: Sat Nov 28 2009 22:40:00

Under the weather and out of a job? You could be eligible for free health services like flu shots and prescription drug refills.

Drug giant Pfizer to pay record $2.3B fineupdated: Wed Sep 02 2009 19:17:00

Pharmaceutical giant Pfizer has agreed to pay a record $2.3 billion settlement to resolve criminal and civil liability for illegally promoting certain pharmaceuticals, the Justice Department announced Wednesday.

CNNMoney: Pfizer fined $2.3B in record fraud settlementupdated: Wed Sep 02 2009 11:30:00

Drug manufacturing giant Pfizer has agreed to pay a $2.3 billion penalty for illegally promoting its pharmaceutical products, the Justice Department announced Wednesday.

CNNMoney: Get a deal on prescription drugsupdated: Mon Jun 15 2009 10:14:00

Paying for prescription drugs is getting harder. New drugs are more expensive than they used to be and consumers are shouldering more of the out-of-pocket costs. Here's how you can cut the cost of prescription drugs.

Fortune: Your TARP funds at work, on Wall Streetupdated: Tue Jan 27 2009 18:46:00

Pfizer's blockbuster $68 billion acquisition of Wyeth sure has the whiff of nostalgia about it. Not only was the deal announced on a Monday morning after a weekend of furtive negotiating - when was the last time a major deal, rather than a bailout, was announced on a Monday morning? - but also its massive size and the fact that seven banks "advised" on it also seemed to be a return to the good old days of 2006 and early 2007 when Merger Mondays were all the rage.

Fortune: Will merger be Pfizer's miracle drug?updated: Tue Jan 27 2009 12:33:00

Wall Street analysts have been urging pharma giant Pfizer to do something big and something soon. So that's what Pfizer did. The company's proposed acquisition of Wyeth in a deal valued at $68 billion is big, in fact the biggest pharma deal in almost a decade. But is it the right thing to fix Pfizer's particular set of problems? The New York City-based company has faced increased scrutiny as the looming expiration of its blockbuster statin drug Lipitor, which brings in about a quarter of Pfizer's revenue, is set to expire in 2011. What's more, the flow of new drugs through the company's pipeline has slowed considerably.

CNNMoney: Pfizer to ax up to 8% of R&D staffupdated: Tue Jan 13 2009 14:30:00

The pharma giant Pfizer said it is cutting up to 8% of its research staff.

Fortune: The case for Pfizerupdated: Mon Dec 01 2008 13:17:00

At first glance, Pfizer seems more virile than ever. The pharmaceutical giant has a sector-leading $26 billion in cash, and its profits last quarter were triple the year before. Pfizer's portfolio includes household names such as Viagra, the famous blue impotency pill, and Lipitor, the anti-cholesterol drug that is the world's best-selling medication. Pfizer Launches Site Weighing Drug Risks, Benefitsupdated: Mon Sep 15 2008 12:20:00

Amid the deluge of drug advertising and news about safety issues, plenty of patients are bewildered over how to weigh the risks and benefits of a medication, or even how to find out what they are FDA Warns Pfizer on Viagra Adsupdated: Mon Apr 21 2008 18:00:00

Federal regulators have warned Pfizer Inc. for not mentioning the risks of Viagra in an advertisement featuring country musicians singing the praises of its popular impotency pill

CNNMoney: Pfizer bumps up sales forecastupdated: Wed Jan 23 2008 12:57:00

Pfizer, the world's largest drugmaker, reported adjusted quarterly earnings that exceeded Wall Street's estimates on Wednesday and lifted its full-year sales outlook.

CNNMoney: Pharma looks strong, biotechs mixed in 2008updated: Fri Dec 21 2007 16:23:00

Big Pharma, fueled by promising pipelines and cost-cutting, is poised for a strong 2008, analysts say, while projections are mixed for the biotech sector.

Fortune: Big Pharma's tough medicineupdated: Thu Dec 13 2007 11:17:00

It's been a rough 2007 for Big Pharma workers. Crippled by mounting competition and slowing pipelines, the country's largest drugmakers have announced plans to shed a record number of jobs this year - more than 30,000 at last count - that are unlikely to ever return.

Fortune: Don't count Pfizer outupdated: Mon Dec 03 2007 13:27:00

It's been hard for Pfizer, the world's largest drugmaker, to catch a break lately.

CNNMoney: Pfizer looks to Asia for manufacturingupdated: Fri Nov 30 2007 07:52:00

U.S. pharmaceutical company Pfizer Inc. is looking to outsource as much as 30 percent of its manufacturing, much of it to Asia, Martin MacKay, head of Pfizer's global research and development, said Friday.

Fortune: 2008 drug sales: Slowest growth in 4 decadesupdated: Thu Nov 01 2007 14:06:00

A closely-watched forecast of drug industry revenue growth released today projects that sales in 2008 will expand at their slowest pace in more than four decades. The reason: A combination of virtually empty Big Pharma product pipelines and increasing price competition from inexpensive generic drugs.

Fortune: Why the Sanofi-Pfizer rumor makes senseupdated: Wed Oct 10 2007 12:08:00

In the last week of trading, shares of French drugmaker Sanofi-Aventis have jumped 5.5% on rumors that U.S. pharma giant Pfizer is pondering the purchase of a significant share of its business. There are two hypothetical scenarios now circulating the markets. One of them makes sense for Pfizer. The other? Not so much.

Fortune: New Pfizer R&D head tries to think smallupdated: Mon Oct 08 2007 10:29:00

Pfizer's newly-appointed chief scientist Martin Mackay wants to help the company think small.

CNNMoney: SEC asks top firms about exec payupdated: Fri Aug 31 2007 08:12:00

The Securities and Exchange Commission has asked the top brass of nearly 300 U.S. companies to better explain the pay packages of top executives, according to a report Friday.

Fortune: Why a Pfizer-Wyeth merger is a bad ideaupdated: Thu Aug 23 2007 21:36:00

You'd think it was 1999 all over again.

CNNMoney: Pfizer picks telecom exec to head financeupdated: Wed Aug 22 2007 00:27:00

Pfizer said Wednesday that it named an industry outsider, Alcatel-Lucent executive Frank D'Amelio, as chief financial officer of the struggling drugmaker.

CNNMoney: FDA accuses Pfizer of false advertisingupdated: Tue Aug 14 2007 03:07:00

The FDA on Monday accused Pfizer of false advertising for its anti-schizophrenia drug Geodon. FDA Approves Novel Drug AIDS Patientsupdated: Mon Aug 06 2007 18:00:00

The government approved a novel drug Monday to help patients with the AIDS virus who are running out of options, while acknowledging lingering questions about the pills' long-term effects

CNNMoney: Pfizer boosts late-stage drug testsupdated: Mon Aug 06 2007 05:13:00

Pfizer Inc., the world's biggest pharmaceutical company, Monday said it increased the number of experimental drugs in the final testing stages and pledged to triple its late-stage portfolio by 2009.

CNNMoney: Street's bullish on Big Pharma earningsupdated: Mon Jul 16 2007 02:52:00

The Street is bullish on Big Pharma, and experts believe the launch of new, fast-growing drugs fueled earnings for most of the major U.S. drugmakers in the second quarter. Anti-Smoking Pill May Help Curb Drinkingupdated: Tue Jul 10 2007 17:15:00

A single pill appears to hold promise in curbing the urges to both smoke and drink, according to researchers trying to help people overcome addiction by targeting a pleasure center in the brain

CNNMoney: Bristol-Pfizer anti-clotting drug clears hurdleupdated: Sun Jul 08 2007 07:58:00

An experimental anti-clotting medicine from Bristol-Myers Squibb Co. and Pfizer Inc. met its main effectiveness and safety goals in a mid-stage study, researchers said Sunday, positioning it as a future option over current popular but problematic drugs.

CNNMoney: Approval of Pfizer AIDS drug delayedupdated: Wed Jun 20 2007 22:56:00

Pfizer Inc. said Wednesday that U.S. health regulators will approve its novel AIDS drug called maraviroc once certain conditions have been met, although the world's biggest drugmaker did not elaborate on what was necessary to obtain outright approval.

CNNMoney: Pfizer abandons trials on lung cancer drugupdated: Wed Jun 20 2007 03:08:00

Pfizer Inc. said on Wednesday it has discontinued trials of an experimental lung cancer drug licensed from Coley Pharmaceutical Group after an independent review committee deemed it ineffective, spurring a 60 percent decline in Coley shares.

Fortune: Pfizer Ranks No. 39 on the 2007 Fortune 500updated: Mon Jun 11 2007 16:23:00

Pfizer (PFE) ranks no. 39 on FORTUNE's list of America's largest corporations.

Fortune: A Big Pharma whistleblower blogs on drugsupdated: Wed Jun 06 2007 05:52:00

Peter Rost is worked up about pink cupcakes. The ex-Pfizer senior executive turned blogger believes he has uncovered another instance of unethical marketing by Big Pharma. Today he's taking on Astr... Nigeria Files Suit Against Pfizerupdated: Wed May 30 2007 17:50:00

Authorities in northern Nigeria have filed a $2 billion civil case and were preparing criminal charges against the U.S. drug company Pfizer

Money Magazine: Where the bargains are nowupdated: Thu May 10 2007 09:34:00

The Dow has been setting record highs recently, but the market still contains pockets of undervalued stocks.

CNNMoney: Pfizer earnings squeezedupdated: Fri Apr 20 2007 14:39:00

Pfizer's first-quarter earnings managed to beat analyst forecasts Friday despite the patent loss of the blood pressure blockbuster Norvasc and anemic sales from the new diabetes product Exubera.

CNNMoney: Drugmakers to take earnings medicineupdated: Mon Apr 16 2007 13:06:00

This is a big week for the U.S. drug industry's earnings, with mixed results expected from a slew of brand-name drugmakers that carry a common theme: getting squeezed by the loss of blockbuster products.

CNNMoney: Pity the poor pharmaceutical sales repupdated: Mon Apr 02 2007 15:33:00

It's hard out there for drug sales reps--particularly if they work in places where gaining access to doctors is becoming increasingly difficult.

CNNMoney: New hope for HIV patients from Merck, Pfizerupdated: Wed Feb 28 2007 10:11:00

Merck and Pfizer are giving AIDS patients something to hope for: a new generation of experimental drugs that could prolong their lives.

CNNMoney: Pfizer to cut 10,000 jobs, shut 5 plantsupdated: Mon Jan 22 2007 06:30:00

Pfizer announced Monday that it will cut 10,000 jobs and close five plants, including three R&D sites and two factories, by the end of 2008, and said its quarterly earnings grew but sales were little changed.

CNNMoney: Pfizer plan fails to wow Wall Streetupdated: Tue Jan 16 2007 11:36:00

Pfizer appears to be getting ready to slash thousands more workers and shut down some of its plants, but part two of CEO Jeffrey Kindler's plan to revitalize the struggling drugmaker did not inspire rave reviews on Wall Street Tuesday.

Fortune: Is outsourcing the prescription for Pfizer?updated: Wed Dec 06 2006 10:30:00

With the failure of torcetripib behind it, Pfizer is now likely to play to its strengths to add more medicines to its pipeline.

Money Magazine: Investing after Pfizer's flop - 3 strategiesupdated: Mon Dec 04 2006 17:55:00

Pfizer's decision to suspend tests of its latest drug for the treatment of high cholesterol underscores the key problem facing most large pharmaceutical companies. Once a drugmaker has reached a certain size, it's an enormous challenge to generate new blockbusters fast enough to maintain a high growth rate.

CNNMoney: Big mergers, big rallyupdated: Mon Dec 04 2006 17:32:00

Stocks surged Monday, sending the the S&P 500 to a fresh six-year high, as investors welcomed a slew of merger news and a slump in oil prices.

CNNMoney: Stock rally rechargesupdated: Mon Dec 04 2006 14:31:00

Stocks surged Monday, pushing the Dow up about 100 points and sending the S&P 500 near a fresh six-year high, as investors welcomed a slew of merger news and a slump in oil prices.

Fortune: When Big Pharma gets too bigupdated: Mon Dec 04 2006 13:10:00

For as long as anyone on Wall Street can remember, Pfizer executives have promised to follow up Lipitor, the company's blockbuster cholesterol pill, with something even bigger and better.

CNNMoney: Big mergers drive big rallyupdated: Mon Dec 04 2006 13:02:00

Stocks surged Monday, pushing the Dow up about 100 points and sending the S&P 500 near a fresh six-year high, as investors welcomed a slew of merger news and a slump in oil prices.

CNNMoney: Mergers spur stocksupdated: Mon Dec 04 2006 11:18:00

A wave of merger news and a slump in oil prices helped fire up the stock market near midday Monday, with investors returning with gusto after last week's declines.

CNNMoney: Upbeat start on Wall Streetupdated: Mon Dec 04 2006 09:35:00

A slew of merger news and a slide in oil prices were among the factors lifting stocks Monday morning, tempering concerns about Pfizer after it halted development of a key new drug.

CNNMoney: Wall Street shrugs off Pfizerupdated: Mon Dec 04 2006 09:23:00

Shares rose Monday as merger news in various industries trumped bad news from Pfizer that it's touted experimental cholesterol dug had to be scrapped.

CNNMoney: Drug downer, deals move marketsupdated: Mon Dec 04 2006 06:35:00

Stocks were looking for direction early Monday, as problems for drugmaker Pfizer sent the shares of that Dow component sharply lower in European trading but could be balanced by some multi-billion dollar mergers..

CNNMoney: Dodgy outlook for Wall Streetupdated: Mon Dec 04 2006 05:49:00

Stocks were looking for direction early Monday, despite problems for drugmaker Pfizer which sent the shares of that Dow component sharply lower in European trading.

CNNMoney: Stocks rise, day 2updated: Wed Nov 29 2006 17:43:00

Stocks surged Wednesday, rising for a second straight session, as investors welcomed a surprisingly strong read on GDP growth, which helped soothe worries about the speed of the economic slowdown.

CNNMoney: Pfizer stock gains on job cutsupdated: Wed Nov 29 2006 11:20:00

Analysts and investors are giving Pfizer the thumbs up for its job-slashing announcement.

CNNMoney: Bullish morning on Wall Streetupdated: Wed Nov 29 2006 10:07:00

Stocks surged Wednesday morning, as investors welcomed a better-than-expected read on economic growth, a mixed read on housing and some company news from Pfizer and Ford Motor.

CNNMoney: Pfizer to slash U.S. sales forceupdated: Tue Nov 28 2006 16:41:00

Pfizer said it would cut its U.S. sales force by 20 percent as part of an ongoing effort to reduce costs.

CNNMoney: Pfizer, Lilly, Wyeth beat forecastsupdated: Thu Oct 19 2006 11:36:00

Big Pharma companies Pfizer, Lilly and Wyeth beat analysts' expectations Thursday with reports of strong gains in third-quarter earnings, though Pfizer isn't expecting annual profit growth until 2009 and is ramping up its already ambitious cost-cutting efforts.

CNNMoney: Stocks stumble on jobs reportupdated: Fri Oct 06 2006 13:09:00

Stocks slipped Friday afternoon, following a mixed read on the labor market in September, with the Dow industrials retreating after hitting a record high in the previous session.

Fortune: Pfizer ranks No. 101 on FORTUNE's 2006 Global 500updated: Wed Sep 20 2006 21:11:00

Pfizer ranks no. 101 on FORTUNE's Global 500 this year, with $51.4 billion in revenues, down 3% from the previous year. The New York, New York-based company was ranked no. 75 on the 2005 list. Its 2005 profits were $8.1 billion, down 28.8% from a year earlier. 2005 was a banner year for most Global 500 companies.

CNNMoney: Pfizer's new CEO outlines the future of healthcareupdated: Wed Sep 20 2006 16:09:00

Pfizer's newly-anointed chief executive Jeffrey Kindler told analysts that his company will balance the opportunities of an expanding market and an aging population, with the limits imposed by healthcare systems around the world.

CNNMoney: Novo Nordisk sues Pfizer over Exuberaupdated: Wed Aug 02 2006 10:53:00

Novo Nordisk has sued Pfizer, alleging that the new product Exubera violates patents on inhalable insulin for diabetics.

CNNMoney: A to-do list for Pfizer's Kindlerupdated: Wed Aug 02 2006 06:00:00

The biggest drug company in the world has a new man at the helm, and analysts are hoping Jeffrey Kindler won't make the same mistakes as his outgoing predecessor, Henry McKinnell.

CNNMoney: Pfizer names new CEOupdated: Fri Jul 28 2006 17:45:00

Pfizer named Jeffrey Kindler, the company's general counsel, to succeed Henry "Hank" McKinnell as CEO of the world's largest pharmaceutical company, the company announced Friday.

CNNMoney: Pfizer needs more drugsupdated: Mon Jul 17 2006 13:58:00

The world's biggest drugmaker is launching a potential blockbuster today, but it's going to take more than that for the company to pull out of its rut.

CNNMoney: When it comes to Sepracor, buyers bewareupdated: Tue Jun 20 2006 14:09:00

Pfizer and Schering-Plough could easily snap up the smaller drugmaker Sepracor but industry analysts say risks to its two products would limit any potential gains.

Fortune: Growth and incomeupdated: Tue Jun 13 2006 10:57:00

Here we look for what Jeremy Siegel calls "corporate El Dorados" - those titans that rack up long stretches of solid profitability. In his latest book, The Future for Investors (Random House, 2005), the Wharton finance professor shows how companies that have marketed "tried-and-true" products for decades in slow-growth or even declining industries have superior returns to firms that develop "the bold and the new."

CNNMoney: Report: Bids for Pfizer unit top $14Bupdated: Wed Jun 07 2006 06:44:00

Drugmaker Pfizer received bids worth more than $14 billion for its consumer products unit, which includes well-known products like Listerine, Rolaids and Sudafed, according to a published report.

CNNMoney: Paper: Pfizer's Nigeria drug test illegalupdated: Fri May 05 2006 23:39:00

WASHINGTON, May 6 (Reuters) - Nigerian medical experts concluded Pfizer Inc. violated international law during a 1996 epidemic by testing an unapproved drug on children with brain infections, the Washington Post reported in Sunday editions, citing a copy of the panel's confidential report.

Fortune: Pfizer's Puzzleupdated: Thu Apr 13 2006 11:49:00

IS Hank McKinnell a failure? A success? Or something in between? Those are the questions people in and out of Pfizer are pondering as its CEO enters his final years on the job.

Fortune: And the next Pfizer CEO is...updated: Fri Apr 07 2006 10:46:00

If only the rest of Big Pharma were as lucky as Pfizer. In the midst of what most top-level managers agree is a CEO talent drought, the New York-based pharma-colossus has no less than three potential CEOs vying to take over when current top guy Hank McKinnell retires in 2008. But there are quite a few sharp elbows being thrown in the race to the top.

CNNMoney: Big Pharma thinks smallupdated: Thu Mar 23 2006 11:46:00

With $100 billion worth of branded drugs losing patent protection in the next five years, Big Pharma needs new drugs -- and licensing from smaller companies is proving to be a cheaper, less risky way of securing potential products than buying those companies outright.

CNNMoney: Pfizer: Potential buyers knocking on its doorupdated: Mon Mar 20 2006 13:49:00

Potential buyers are knocking on Pfizer's door for its $10 billion consumer products division, and people are scratching their heads over what the company plans to once they get their hands on the money.

CNNMoney: Pfizer's comeback trailupdated: Thu Mar 09 2006 13:31:00

Pfizer stock's got battered and bloodied last year, but it's making a comeback.

CNNMoney: More good times ahead for biotechsupdated: Thu Feb 23 2006 09:21:00

Drug sales, bolstered by Medicare coverage, are projected to keep rising for the next 10 years, and biotechs are expected to get the lion's share of that increase, while the more traditional Big Pharma companies get squeezed by generic drug makers.

CNNMoney: Good times ahead for biotechsupdated: Wed Feb 22 2006 14:55:00

Drug sales, bolstered by Medicare coverage, are projected to keep rising for the next 10 years, and biotechs are expected to get the lion's share of that increase, while the more traditional Big Pharma companies get squeezed by generic drug makers.

Money Magazine: Sivy 70updated: Thu Feb 16 2006 10:13:00

Losers outnumbered winners in late December and early January. As the year turned, 37 of the 70 stocks posted a decline and only 32 rose (IBM was unchanged). Six stocks--Aetna, CVS, DuPont, Genente...

CNNMoney: Pfizer sees '06 profit slightly under the weatherupdated: Fri Feb 10 2006 09:26:00

Pfizer Inc. gave earnings guidance Friday that was below analysts' estimates.

CNNMoney: Trying for a comebackupdated: Thu Jan 19 2006 08:48:00

Stocks got a boost at the open Thursday after better-than-expected earnings from Pfizer and Merrill calmed concerns about corporate results.

CNNMoney: Pfizer set to report sales slumpupdated: Tue Jan 17 2006 14:13:00

Have you seen Pfizer's stock price lately? It could be worse. In fact, it has been worse.

CNNMoney: 3 stocks for incomeupdated: Tue Dec 20 2005 08:10:00

Federal Reserve chairman Alan Greenspan raised short-term interest rates last week to 4.25 percent, the highest level in 4-1/2 years.

CNNMoney: Stocks see three-session slideupdated: Mon Dec 19 2005 09:55:00

Stocks ended lower for the third consecutive session Monday, reversing earlier advances as tech concerns and economic anxiety outweighed a big Pfizer patent victory and falling oil prices.

CNNMoney: Year-end struggle on Wall Streetupdated: Mon Dec 19 2005 09:35:00

Stocks struggled early Monday as a jump in shares of Pfizer after a patent ruling weren't enough to ignite a broader round of buying.

CNNMoney: Pfizer: A pill worth swallowing?updated: Mon Dec 19 2005 07:31:00

After the market closed on Friday and trading floors began to empty for the holidays, there suddenly came long-awaited and momentous news about one of the world's biggest companies.

Money Magazine: Look Deeper and This Market's Not So Dullupdated: Mon Dec 12 2005 16:42:00

the time to ignore stocks. The Dow Jones industrial average may not be very active, but beneath the surface of today's market, there's actually quite a lot going on. ...

Fortune: Hall of Fameupdated: Mon Nov 14 2005 00:01:00

CALL THEM the Big Eight. Of the 50 women on the power list, only these highfliers are at the very top of their companies--as chair or CEO. By order of ranking, they are Meg Whitman, eBay; Anne Mulc...

Fortune: What Ails Health Stocks? updated: Mon Nov 14 2005 00:01:00

Picking stocks is an inexact science--so inexact you can be wrong even when you're right. Just consider the story we did on health-care stocks back in May 2004. (See "Rx for Investors" on We argued that the health-care sector would continue to outpace the broader stock market, just as it has since the mid-1990s, serving the medical needs of an aging populace. "There's no denying the sheer market potential of 75 million trick-kneed, Prevacid-popping, ointment-loving consumers," we wrote. "You can almost hear the cash registers ring." Well, a year and a half later, the only thing ringing has been alarm bells. Concerns about drug patent expirations and meager new-product pipelines have sidetracked pharmaceutical stocks. Pharma industry tracker IMS Health expects growth in drug sales in 2006 to be the lowest in ten years. And in the medical devices arena, fierce competition and increased pricing pressure are crimping earnings growth. The Feds aren't helping either: In September, Guidant, Medtron

CNNMoney: Investors, peep at these pipelinesupdated: Tue Nov 01 2005 11:52:00

If the future of Big Pharma can be read in its pipelines, Eli Lilly & Co. and Sanofi-Aventis are among the few bright spots, analysts say -- but investors should also look at Pfizer, which is experimenting with a drug combo that could outsell all others.

CNNMoney: Pfizer CEO grilled over hazy outlookupdated: Thu Oct 20 2005 14:26:00

Pfizer CEO Henry McKinnell got grilled by industry analysts Thursday after the world's biggest drugmaker pulled its financial guidance for 2006 and 2007.

We recommend